var data={"title":"Thyrotropin alfa (recombinant human thyrotropin): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Thyrotropin alfa (recombinant human thyrotropin): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7049?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=thyrotropin-alfa-recombinant-human-thyrotropin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Thyrotropin alfa (recombinant human thyrotropin): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227397\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Thyrogen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227398\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Thyrogen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227410\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Diagnostic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227399\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Note:</b> Consider pretreatment with glucocorticoids for patients in whom local tumor expansion may compromise vital anatomic structures (such as trachea, CNS, or extensive macroscopic lung metastases). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diagnostic imaging:</b> IM: 0.9 mg, followed 24 hours later by a second 0.9 mg dose; obtain serum Tg sample 72 hours after the second thyrotropin alfa injection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyroid tissue remnant ablation:</b> IM: 0.9 mg, followed 24 hours later by a second 0.9 mg dose. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Radioiodine administration should be given 24 hours following the second thyrotropin alfa injection (for diagnostic scanning and remnant ablation). Perform diagnostic scanning 48 hours after radioiodine administration (72 hours after the second thyrotropin alfa injection). Post-therapy scanning may be delayed (additional days) to allow decline of background activity. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227400\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15159240\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, elimination is significantly slower in dialysis-dependent end-stage renal impairment and TSH level elevation may be prolonged.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22460102\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227385\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Thyrogen: 1.1 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227373\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227387\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer only by IM injection into the buttock. Do <b>not</b> administer intravenously.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227386\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diagnostic imaging:</b> Adjunctive diagnostic tool for serum thyroglobulin (Tg) testing (with or without radioiodine imaging) in follow up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Thyrotropin alfa-stimulated Tg levels are generally lower than and do not correlate with Tg levels after thyroid hormone withdrawal; even when thyrotropin alfa-stimulated Tg testing is performed in combination with radioiodine imaging, there is a risk of missing a thyroid cancer diagnosis or of underestimating disease extent; anti-Tg antibodies may confound Tg assay and render Tg levels uninterpretable, in such cases, even with a negative or low-stage thyrotropin alfa radioiodine scan, consider further patient evaluation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyroid tissue remnant ablation: </b> Adjunctive treatment for radioiodine ablation of thyroid tissue remnants after total or near-total thyroidectomy in patients with well-differentiated thyroid cancer without evidence of metastatic disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: The effect of thyrotropin alfa on long-term thyroid cancer outcomes has not been determined. Due to relatively small clinical experience, it is not possible to conclude if long-term thyroid cancer outcomes would be equivalent after thyrotropin alfa use or withholding thyroid hormone for TSH elevation prior to remnant ablation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227416\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Thyrogen may be confused with Thyrolar</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227380\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Gastrointestinal: Nausea (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (6%), dizziness (2%), fatigue (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined: Endocrine &amp; metabolic: Altered thyroid hormone levels (increased)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Cerebrovascular accident (with and without physiologic symptoms like unilateral weakness), flu-like symptoms (transient; including arthralgia, chills, fever, malaise, myalgia, shivering), hypersensitivity reaction (including dyspnea, flushing, pruritus, skin rash, urticaria), injection site reaction (including bruising, erythema, pain, and pruritus)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227390\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>U.S. labeling:</i> There are no contraindications listed in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to thyrotropin alfa or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227377\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperthyroidism: Thyrotropin alfa use may cause a transient (over 7 to 14 days) and significant rise in serum thyroid hormone concentration in patients with substantial<i> in situ</i> thyroid tissue or with functional thyroid cancer metastases. Thyrotropin alfa&ndash;induced hyperthyroidism may result in serious complications in patients with certain risk factors (heart disease, extensive metastatic disease or with underlying serious illness); consider hospitalization for administration and subsequent observation. Deaths within 24 hours of thyrotropin alfa administration have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Stroke: Postmarketing reports of stroke or symptoms suggestive of stroke (eg, unilateral weakness) have occurred within 3 days of administration in patients without known central nervous system metastases. A majority of these patients had risk factors for stroke (eg, smokers or history of migraine) or were young women taking oral contraceptives. Patients should be well hydrated prior to administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tumor growth: Sudden, rapid, and painful growth of residual thyroid tissue or distant metastases may occur following thyrotropin alfa administration. Symptoms are associated with tissue location and include acute hemiplegia, hemiparesis, and vision loss 1 to 3 days after administration. Laryngeal edema, pain at site of distant metastases, and respiratory distress requiring tracheotomy have also been reported. Consider glucocorticoid premedication in patients where local tumor enlargement may compromise vital structures (trachea, CNS, or extensive macroscopic lung metastases).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Patients with known history of heart disease in the presence of significant residual thyroid tissue are at increased risk for thyrotropin alfa-induced hyperthyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Thyrotropin alfa elimination is significantly reduced in dialysis-dependent end-stage renal impairment, leading to prolonged elevation of TSH levels. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Elderly patients with residual thyroid tissue are at increased risk for thyrotropin alfa-induced hyperthyroidism</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300137\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6223312\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10286&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227383\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2738770\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Effects on the fetus or pregnant woman are unknown.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17917300\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if thyrotropin alfa is excreted in breast milk. The manufacturer recommends that caution be exercised when administering thyrotropin alfa to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15159242\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Neurologic adverse events (hemiplegia, hemiparesis, stroke, weakness); dyspnea, dysphonia, stridor or other symptoms of local tumor growth</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227376\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Thyrotropin alfa, derived from a recombinant DNA source, has the identical amino acid sequence as endogenous human thyroid stimulating hormone (TSH). As a diagnostic tool in conjunction with serum thyroglobulin (Tg) testing, thyrotropin alfa stimulates the secretion of Tg from any remaining thyroid tissues (remnants). Under conditions of successful thyroidectomy and complete ablation, very little serum Tg should be detected under TSH stimulatory conditions; conversely, elevated Tg levels suggest the presence of remnant thyroid tissues. Since the source of TSH is exogenous, stimulation of Tg synthesis can be achieved in euthyroid patients, avoiding the need for thyroid hormone withdrawal.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">As an adjunctive agent for radioiodine ablation treatment of thyroid cancer tissue remnants, thyrotropin alfa binds to TSH receptors on these tissues, stimulating the uptake and organification of iodine, including radiolabeled iodine (I<sup>131</sup>). Cancerous tissue is destroyed via gamma emission from the radioiodine concentrated in these tissues.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227389\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 25 &plusmn; 10 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Median: 10 hours (range: 3-24 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323966\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Thyrogen Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.1 mg (1): $1,784.34</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F227391\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Thyrogen (AT, AU, BE, BR, CH, CL, CY, CZ, DE, DK, EE, ES, FI, FR, GR, HK, HN, HR, IE, IL, IS, IT, JP, KR, LB, LT, LU, LV, MT, MY, NL, NO, PE, PL, PT, RO, SE, SG, SI, SK, TH, TR, TW, UY);</li>\n      <li>Tyrohen (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Haugen BR, Pacini F, Reiners C, et al, &ldquo;A Comparison of Recombinant Human Thyrotropin and Thyroid Hormone Withdrawal for the Detection of Thyroid Remnant or Cancer,&rdquo; <i>J Clin Endocrinol Metab</i>, 1999, 94(11):3877-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thyrotropin-alfa-recombinant-human-thyrotropin-drug-information/abstract-text/10566623/pubmed\" target=\"_blank\" id=\"10566623\">10566623</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mallick U, Harmer C, Yap B, et al, &ldquo;Ablation With Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer,&rdquo; <i>N Engl J Med</i>, 2012, 366(18):1674-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thyrotropin-alfa-recombinant-human-thyrotropin-drug-information/abstract-text/22551128/pubmed\" target=\"_blank\" id=\"22551128\">22551128</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pacini F, Ladenson PW, Schlumberger M, et al, &ldquo;Radioiodine Ablation of Thyroid Remnants After Preparation With Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study,&rdquo; <i>J Clin Endocrinol Metab</i>, 2006, 91(3):926-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thyrotropin-alfa-recombinant-human-thyrotropin-drug-information/abstract-text/16384850/pubmed\" target=\"_blank\" id=\"16384850\">16384850</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schlumberger M, Catargi B, Borget I, et a, &ldquo;Strategies of Radioiodine Ablation In Patients With Low-Risk Thyroid Cancer,&rdquo; <i>N Engl J Med</i>, 2012, 366(18):1663-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thyrotropin-alfa-recombinant-human-thyrotropin-drug-information/abstract-text/22551127/pubmed\" target=\"_blank\" id=\"22551127\">22551127</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schroeder PR, Haugen BR, Pacini F, et al, &ldquo;A Comparison of Short-Term Changes in Health-Related Quality of Life in Thyroid Carcinoma Patients Undergoing Diagnostic Evaluation With Recombinant Human Thyrotropin Compared With Thyroid Hormone Withdrawal,&rdquo; <i>J Clin Endocrinol Metab</i>, 2006, 91(3):878-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/thyrotropin-alfa-recombinant-human-thyrotropin-drug-information/abstract-text/16394083/pubmed\" target=\"_blank\" id=\"16394083\">16394083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thyrogen (thyrotropin alfa for injection) [prescribing information]. Cambridge, MA: Genzyme Corporation; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thyrogen (thyrotropin alfa) [product monograph]. Mississauga, ON, CA: Sanofi Genzyme Canada; November 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10286 Version 87.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F227397\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F227398\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F227410\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F227399\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F227400\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15159240\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22460102\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F227385\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F227373\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F227387\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F227386\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F227416\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F227380\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F227390\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F227377\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300137\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6223312\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F227383\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2738770\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F17917300\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F15159242\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F227376\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F227389\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323966\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F227391\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10286|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=thyrotropin-alfa-recombinant-human-thyrotropin-patient-drug-information\" class=\"drug drug_patient\">Thyrotropin alfa (recombinant human thyrotropin): Patient drug information</a></li></ul></div></div>","javascript":null}